News

Novo Nordisk's CFO sceptical Trump executive order on drug manufacturing can cut timelines
Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to ...
Novo Nordisk CFO on Wegovy, Tariffs, US Compounding
Novo Nordisk CFO Karsten Munk Knudsen speaks on Bloomberg Television about earnings, tariffs and the impact of compounding in ...
NJBIZ13h
Novo Nordisk seeks FDA approval for Wegovy weight loss pill
Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...
Novo Nordisk cuts forecasts, shares rise ahead of FDA ban on Wegovy copycats
Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) - Obesity drugmaker Novo Nordisk cut its sales forecasts on Wednesday ...
Novo Nordisk: Q1 Earnings Snapshot
BAGSVAERD, Denmark (AP) — BAGSVAERD, Denmark (AP) — Novo Nordisk A/S (NVO) on Wednesday reported first-quarter earnings of $4.09 billion. The Bagsvaerd, Denmark-based company said it had profit of 92 ...
Novo Nordisk CFO doubts Trump’s order will speed up pharma plant approvals
Investing.com -- Novo Nordisk (NYSE: NVO )’s CFO, Karsten Munk Knudsen, expressed doubts on Wednesday about the potential impact of U.S. President Donald Trump’s recent executive order on the ...
Trending tickers: AMD, Novo Nordisk, Rivian, Super Micro and Trainline
Novo Nordisk (NVO, NOVO-B.CO) said first-quarter sales of its first-to-market weight-loss drug Wegovy were 17.36bn Danish ...